Acutaas Chemicals Ltd
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]
- Market Cap ₹ 9,385 Cr.
- Current Price ₹ 1,146
- High / Low ₹ 1,322 / 600
- Stock P/E 59.1
- Book Value ₹ 160
- Dividend Yield 0.13 %
- ROCE 19.9 %
- ROE 16.0 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 41.4% CAGR over last 5 years
Cons
- Stock is trading at 7.17 times its book value
- Company has a low return on equity of 13.8% over last 3 years.
- Promoter holding has decreased over last 3 years: -5.09%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
160 | 188 | 239 | 240 | 341 | 520 | 617 | 717 | 1,007 | |
137 | 157 | 196 | 198 | 260 | 415 | 493 | 589 | 775 | |
Operating Profit | 23 | 31 | 42 | 42 | 80 | 105 | 123 | 128 | 232 |
OPM % | 14% | 16% | 18% | 17% | 24% | 20% | 20% | 18% | 23% |
0 | 3 | 0 | 2 | 1 | 3 | 4 | -25 | 17 | |
Interest | 3 | 3 | 5 | 6 | 6 | 6 | 2 | 6 | 6 |
Depreciation | 1 | 2 | 3 | 4 | 4 | 10 | 12 | 16 | 27 |
Profit before tax | 19 | 28 | 35 | 35 | 72 | 91 | 112 | 82 | 216 |
Tax % | 35% | 35% | 34% | 21% | 25% | 21% | 26% | 41% | 26% |
12 | 18 | 23 | 27 | 54 | 72 | 83 | 49 | 160 | |
EPS in Rs | 40.17 | 61.67 | 11.10 | 13.08 | 8.57 | 9.87 | 11.43 | 5.80 | 19.38 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 15% | 13% | 26% | 8% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 33% |
3 Years: | 25% |
TTM: | 40% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 41% |
3 Years: | 30% |
TTM: | 167% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 30% |
1 Year: | 67% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 16% |
3 Years: | 14% |
Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 2 | 10 | 10 | 32 | 36 | 36 | 37 | 41 |
Reserves | 37 | 56 | 72 | 101 | 135 | 486 | 558 | 637 | 1,269 |
27 | 44 | 54 | 59 | 137 | 1 | 4 | 217 | 13 | |
43 | 54 | 77 | 61 | 110 | 136 | 169 | 205 | 227 | |
Total Liabilities | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 1,096 | 1,549 |
28 | 32 | 79 | 85 | 186 | 205 | 259 | 427 | 570 | |
CWIP | 11 | 30 | 2 | 12 | 0 | 3 | 30 | 125 | 130 |
Investments | 1 | 3 | 2 | 2 | 1 | 2 | 2 | 0 | 0 |
68 | 91 | 131 | 133 | 225 | 450 | 477 | 543 | 848 | |
Total Assets | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 1,096 | 1,549 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
29 | 8 | 15 | 27 | 28 | -12 | 66 | 125 | 118 | |
-19 | -25 | -21 | -24 | -101 | -121 | -33 | -365 | -224 | |
-7 | 15 | 6 | 0 | 72 | 140 | -12 | 239 | 261 | |
Net Cash Flow | 3 | -2 | -0 | 3 | -1 | 8 | 20 | -1 | 156 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 83 | 97 | 116 | 86 | 129 | 115 | 136 | 105 | 105 |
Inventory Days | 76 | 89 | 95 | 148 | 123 | 150 | 131 | 139 | 119 |
Days Payable | 148 | 154 | 168 | 146 | 172 | 158 | 157 | 119 | 103 |
Cash Conversion Cycle | 11 | 31 | 43 | 88 | 80 | 107 | 111 | 125 | 121 |
Working Capital Days | 46 | 64 | 68 | 86 | 119 | 141 | 141 | 132 | 126 |
ROCE % | 38% | 34% | 27% | 33% | 24% | 21% | 16% | 20% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
2d - Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 is enclosed.
-
Announcement under Regulation 30 (LODR)-Joint Venture
27 Jun - Acutaas' subsidiary forms JV in South Korea with KRW 30B investment for semiconductor chemicals manufacturing.
-
Closure of Trading Window
27 Jun - Trading window closed from July 1, 2025, till 48 hours after Q1 results announcement.
-
Intimation Under Reg 30 Of SEBI (LODR) Regulations, 2015
10 Jun - Appointment of K.C Mehta & Co. LLP as internal auditor for FY 2025-26.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
4 Jun - Acutaas officials to attend investor conference June 9-11, 2025 in Singapore and Hongkong.
Annual reports
Concalls
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Oct 2021Transcript PPT
Business Overview
AMI Organics manufactures specialty chemicals with varied end usage, and is focused on development and manufacturing of advanced pharmaceutical intermediates for regulated and generic APIs and New Chemical Entities (NCE), and key starting materials for agrochemical and fine chemicals. [1]